I actually think this is a much more reasonable take than some of the earlier replies, and I agree with parts of it.To be clear, my position is that OP should do something, but that something would most likely be starting with either a GLP OR metformin rather than immediately jumping to both a GLP AND metformin at the same time, unless there's something unique about their situation that justifies dual treatment.
Not directly relevant to OP, but there's a separate mono-therapy VS dual-therapy debate/controversy within the endocrinology space in regards to what is best for treating new diabetics that I'll unpack here, since it's kind of interesting. Historically, a new diabetic was started on metformin alone, to see if lifestyle + metformin was sufficient treatment. Recently the ADA has published arguments from doctors suggesting that starting those patients on metformin + GLP (or SGLT2 or others) right off the bat makes more sense than metformin alone. I don't personally agree with their positions, but I understand why they're making them, since many (perhaps even most) diabetics don't find long-term resolution through metformin alone.
I think such doctors are committing a logical fallacy in advancing that position. It is based on the traditional approach to treating diabetes, which is to start with metformin and keep adding on additional other drugs as the disease progresses, which historically was a sensible way to treat diabetes. Those doctors are assuming a certain inevitability for diabetes that simple doesn't exist anymore with the advent of modern GLP drugs. By being trapped in the thinking that new drugs should be added rather than replaced, pharma benefits through more prescriptions being filled, but many patients will be taking a larger number of different drugs when a modern GLP might very well be sufficient on its own. Although in this case it's not a cash grab (nobody is getting rich off of metformin), but just "we've always done it this way" being mistakenly applied to clinical decision making by a large medical organization.
I also don’t think everyone automatically needs combo therapy. GLP monotherapy is enough for many people.
My pushback is that combination therapy isn’t just an outdated “we’ve always done it this way” thinking. In someone his age, with his score and history of significant insulin resistance despite lifestyle efforts, I don’t think it’s irrational for a doctor to consider lower dose multi pathway treatments.
Whether that added benefit is meaningful enough in the OP’s case is the unknown and the real debate. Not whether the concept itself is irrational.